Sinovac Biotech Ltd (SVA) — Cash Flow Quality Index

Latest as of June 2023: 7.92x

Sinovac Biotech Ltd (SVA) has a Cash Flow Quality Index of 7.92x as of June 2023. Operating cash flow of $578.90 Million exceeds net income of $73.11 Million, indicating high earnings quality where cash backs reported profits. Explore Sinovac Biotech Ltd cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

Cash Flow Quality Index

7.92x
Operating CF / Net Income

Operating Cash Flow

$578.90 Million
USD

Net Income

$73.11 Million
USD

Data as of

Jun 2023
Most recent filing

Sinovac Biotech Ltd Cash Flow Quality Index (2007–2024)

Historical Cash Flow Quality Index for Sinovac Biotech Ltd across 12 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see how efficiently does Sinovac Biotech Ltd generate cash.

Annual Cash Flow Quality Index for Sinovac Biotech Ltd (2007–2024)

Year-by-year earnings quality comparison for Sinovac Biotech Ltd.

Year Quality Index Operating CF (USD) Net Income YoY Change
2024 -0.63x $-56.89 Million $90.91 Million ▲ +92.8%
2022 -8.75x $-770.75 Million $88.13 Million ▼ -923.6%
2021 1.06x $15.35 Billion $14.46 Billion ▼ -59.0%
2020 2.59x $479.31 Million $185.18 Million ▲ +332.0%
2019 0.60x $39.07 Million $65.22 Million ▲ +172.4%
2018 0.22x $7.94 Million $36.11 Million ▼ -86.5%
2017 1.63x $59.76 Million $36.70 Million ▲ +104.5%
2014 -36.30x $-10.13 Million $279.00K ▼ -7674.6%
2013 0.48x $5.58 Million $11.64 Million ▼ -69.9%
2009 1.59x $48.41 Million $30.41 Million ▲ +85.1%
2008 0.86x $10.50 Million $12.22 Million ▲ +52.4%
2007 0.56x $4.32 Million $7.65 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.